Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms – Claims Data Analysis – IBS-Diarrhea

Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. The disorder is generally grouped into three subtypes: constipation-predominant, diarrhea-predominant, and mixed. This analysis focuses on the diarrhea-predominant subtype (IBS-D). Available treatments are limited; few drugs have FDA approval for IBS-D, and most drugs are used off-label. The primary focus remains on alleviating diarrhea symptoms while providing psychological support to patients. Various approaches include the use of antidepressants (off-label), motor stimulants (off-label), anticholinergic agents (off-label), a 5-HTR modulator (Sebela Pharmaceuticals’ Lotronex), an antibiotic (Salix Pharmaceuticals’ Xifaxan), and an opioid delta receptor antagonist (AbbVie’s Viberzi).

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed IBS-D patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed IBS-D patients?
• How have Viberzi and Lotronex been integrated into the treatment algorithm, and what is their source of business?
• What percentage of IBS-D patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
• What percentage of IBS-D patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Markets covered: United States

Key companies: AbbVie, Salix, Sebela Pharmaceuticals

Key drugs: Viberzi, Xifaxan, Lotronex, dicyclomine, hyoscyamine sulfate / scopolamine, SSRIs, SNRIs, tricyclic antidepressants.

Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses